Research Guide
A clear BPC-157 dosage guide covering research protocols, injection amounts, reconstitution math, cycle length, side effects and cited evidence.
If you are researching BPC-157 dosage, this guide separates three things that often get blurred together: what published studies tested, what research-planning references commonly use, and what is simply unknown. It also covers reported benefits, side effects and the syringe math behind commonly cited protocols.
Educational and research information only. Nothing here is medical advice, prescribing guidance or a recommendation to use any compound. Consult a licensed healthcare professional before any health decision.
The BPC-157 literature is almost entirely preclinical. Rodent studies report accelerated tendon-to-bone healing, increased fibroblast outgrowth and migration, protection of the gut lining against NSAID-induced lesions, and effects on vascular tone through the VEGFR2 and nitric-oxide pathways. Pharmacokinetic work in rats and dogs describes rapid clearance.
What is missing is the part that matters most for people: controlled human trials establishing an effective dose, a safe duration, or a real-world effect size. Any dose band you see online — including the ones below — is extrapolated, not trial-tested.
Reference protocols describe subcutaneous administration from a reconstituted vial drawn into a U-100 insulin syringe. The commonly cited bands are:
Injection is often described near the area of interest, though systemic effects in animal models did not appear to depend on injection site.
Concentration is the only thing that turns a dose in micrograms into units on a syringe. Divide the vial strength by the volume of bacteriostatic water added:
Add the water slowly down the vial wall, swirl rather than shake, and store the reconstituted vial refrigerated.
Reference cycles are usually described as 4 to 6 weeks, then a break to reassess. BPC-157 is frequently paired with TB-500 in soft-tissue research planning, and appears in blends such as Wolverine, GLOW and KLOW. Combination protocols have no dedicated human trial data — each component should be understood on its own first.
The same angiogenic activity that supports repair also supports tumour growth. Reviews treat this as an open question and a clear reason for caution in anyone with a current or prior cancer diagnosis. Product quality is a second real-world risk: purity, identity and sterility vary by supplier, so a certificate of analysis matters.
BPC-157 is not FDA approved, appears on the FDA's compounding category-2 list, and has been prohibited by WADA since 2022.
Published research reference
Trial / research dose bands
Reported side effects
Cited studies
Educational research reference only — not medical advice.
What is BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide sequence derived from a protein found in human gastric juice. Nearly all published work is preclinical — rodent and in-vitro models of tendon, ligament, muscle and gut-lining repair. There are no large published human clinical trials.
What is the dosage for BPC-157?
Research-planning references cluster around roughly 250 mcg once daily as a low band, 250 mcg twice daily as the most commonly cited standard, and up to about 500 mcg twice daily for short acute-injury planning. These are research bands, not clinical doses, and no regulator has validated them.
How is BPC-157 reconstituted?
A lyophilised vial is reconstituted with bacteriostatic water added slowly down the vial wall, then swirled — never shaken. The resulting concentration determines syringe units: a 5 mg vial with 2 mL of bacteriostatic water gives 2.5 mg/mL, so 250 mcg is 0.1 mL, or 10 units on a U-100 insulin syringe.
How long is a typical research cycle?
Reference protocols most often describe 4 to 6 week blocks, with a break afterwards to reassess. Longer continuous use has no published human safety characterisation.
Can BPC-157 be taken orally?
Oral and injectable forms both appear in the literature. Much of the gastrointestinal rodent work used oral or intragastric administration, while soft-tissue models more often used injection. Bioavailability in humans is not established for either route.
Is BPC-157 approved, and is it banned in sport?
It is not an FDA-approved drug and in 2023 was placed on the FDA's list of bulk substances raising safety concerns for compounding. WADA added BPC-157 to its prohibited list in 2022, so tested athletes should not use it.
What are the main safety concerns?
The clearest theoretical concern is that the angiogenic pathway supporting tissue repair also supports tumour growth; reviews flag this as unresolved, particularly for anyone with a current or prior cancer diagnosis. Long-term human safety data does not exist.
Track it properly
Members log doses, cycles and outcomes in one place, compare compounds side by side and read the full Peptide Academy breakdown for every compound in this guide.